Shilpa Medicare’s stock jumped over 6% on November 19 after its subsidiary got a key certification from a European regulator. The European Directorate for the Quality of Medicines & Healthcare (EDQM) gave Shilpa Pharma Lifesciences, the company’s subsidiary, the Certificate of Suitability (CEP) for Nifedipine.
Doctors prescribe Nifedipine to treat high blood pressure and chest pain. It works by relaxing arteries, which makes the heart’s job easier. This means the heart doesn’t have to work as hard to pump blood leading to better oxygen supply. The company said this certification shows its dedication to quality and its ability to meet worldwide manufacturing standards.
On November 18, the company’s subsidiary also got a CEP for Octreotide, another crucial drug. Doctors use Octreotide to treat several conditions. These include severe diarrhea acromegaly (a hormone disorder) flushing episodes caused by certain tumors, and watery diarrhea linked to VIP-secreting tumors.
These approvals mark a big step forward for Shilpa Medicare. They boost its standing in the global pharmaceutical industry and show it can produce effective high-quality drugs.
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
